New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
April 28, 2014
04:55 EDTALDR, ALDR, ALDR, ALDR, ALDR, ALDR, CNDO, CNDO, CNDO, CNDO, CNDO, CNDO, ISIS, ISIS, ISIS, ISIS, ISIS, ISIS, PTCT, PTCT, PTCT, PTCT, PTCT, PTCT, OPXA, OPXA, OPXA, OPXA, OPXA, OPXA, SRPT, SRPT, SRPT, SRPT, SRPT, SRPT, XNPT, XNPT, XNPT, XNPT, XNPT, XNPT, SNY, SNY, SNY, SNY, SNY, SNY, BIIB, BIIB, BIIB, BIIB, BIIB, BIIB, SYN, SYN, SYN, SYN, SYN, SYN, CYTK, CYTK, CYTK, CYTK, CYTK, CYTKAmerican Academy of Neurology to hold annual meeting
66th Annual Meeting of the AAN is being held in Philadelphia on April 26-May 3.
News For CYTK;SYN;BIIB;SNY;XNPT;SRPT;OPXA;PTCT;ISIS;CNDO;ALDR From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
1 | 2 | 3 | 4 | all recent news | >>
October 16, 2014
18:16 EDTSRPTSarepta up 10.6% following publication of Ebola phase 1 clinical study
16:13 EDTSRPTSarepta announces publication of Ebola, Marburg Phase I clinical study results
Sarepta Therapeutics announced the publication of results from two single ascending-dose studies that demonstrated no clinical or toxicologic safety concerns with the company’s drug candidates for the treatment of Ebola and Marburg virus, respectively. AVI-6002 for the treatment of Ebola is a combination therapy of two phosphorodiamidate morpholino oligomers, which target the viral matrix proteins VP24 and VP35, respectively. AVI-6003 for the treatment of Marburg is a combination therapy of two PMOs, which target the viral proteins VP24 and NP, respectively. These drug candidates use Sarepta’s advanced and proprietary PMOplus chemistry, which is also the basis of the company’s clinical-stage influenza drug candidate, AVI-7100. Results from previous viral challenge studies of AVI-6002 and AVI-6003 in non-human primates demonstrated prevention of disease development and death following exposure to Ebola or Marburg virus. Subsequent animal studies demonstrated that for each combination therapy, only one oligomer contributed to efficacy, and therefore, the lead drug candidates for Ebola and Marburg have since become the single compounds AVI-7537 and AVI-7288.
08:19 EDTSNYSanofi Pasteur, Immune Design enter collaboration HSV therapy
Immune Design (IMDZ) announced that it has entered into a broad collaboration for the development of a herpes simplex virus, or HSV, immune therapy with Sanofi Pasteur, the vaccines division of Sanofi (SNY). Sanofi Pasteur and Immune Design will each contribute product candidates to the collaboration: Sanofi Pasteur will contribute HSV-529, a clinical-stage replication-defective HSV vaccine product candidate, and Immune Design will contribute G103, its preclinical trivalent vaccine product candidate. The collaboration will explore the potential of various combinations of agents, including leveraging Immune Design's GLAASTM platform, with the goal to select the best potential immune therapy for patients. The two companies will develop the products jointly through Phase 2 clinical trials, at which point Sanofi Pasteur intends to continue development of the most promising candidate and be responsible for commercialization. Sanofi Pasteur will bear the costs of all preclinical and clinical development, with Immune Design providing a specific formulation of GLA from the GLAAS platform at its cost through Phase 2 studies. Immune Design will be eligible to receive future milestone and royalty payments on any product developed from the collaboration; other financial terms of the agreement have not been disclosed.
October 15, 2014
10:49 EDTSRPTEbola linked names rise again amid broader market sell-off
Subscribe for More Information
10:02 EDTSNYOn The Fly: Analyst Upgrade Summary
Subscribe for More Information
09:57 EDTISISLeerink biotech analysts hold an analyst/industry conference call
Subscribe for More Information
07:32 EDTOPXARedChip Companies to hold a virtual conference
Subscribe for More Information
07:29 EDTSNYSelecta, JDRF, Sanofi extend collaboration for SVP immunotherapy
Subscribe for More Information
05:26 EDTSNYSanofi upgraded to Outperform from Neutral at Credit Suisse
October 14, 2014
11:23 EDTBIIB, SNYBIND Therapeutics and The Conference Forum hold a conference
Subscribe for More Information
09:04 EDTSRPTChinese company says drug can cure Ebola, Reuters reports
Subscribe for More Information
09:00 EDTSNYSanofi rotavirus vaccine enters Phase III trials in India
Subscribe for More Information
08:08 EDTSNYRegulus Therapeutics to present new preclinical data on multiple programs
Regulus Therapeutics (RGLS) announced that it will present new preclinical data on multiple programs and an overview of its clinical portfolio at the 10th Annual Oligonucleotide Therapeutics Society meeting being held October 12-October 15 at the Hilton San Diego Resort and Spa. In a poster titled "Anti-Diabetic Activity of miR-103/107 Anti-miRs", Regulus scientists will present preclinical data further demonstrating the potential benefit of a microRNA therapeutic for the treatment of metabolic disorders. In a poster titled "Inhibition of miR-21 with RG-012 Improves Renal Function and Survival in Multiple Strains of Col4A3 Deficient Mice", Regulus scientists, in collaboration with its strategic alliance partner Sanofi (SNY), will present new preclinical data demonstrating that weekly subcutaneous delivery of RG-012 has shown to provide both glomerular and tubule protection in the kidneys of Col4A3 deficient mice in an Alport syndrome model.
October 13, 2014
12:44 EDTSRPTSarepta data supported by DMD study in journal, TheStreet reports
A study published in medical journal PLOS One following the progression of Duchenne muscular dystrophy supports Sarepta's push for accelerated approval of eteplirsen, TheStreet's Adam Feuerstein reports. Reference Link
07:35 EDTCYTKCytokinetics announces development program update for CK-2127107
Subscribe for More Information
07:12 EDTISISOligonucleotide Therapeutics Society to hold annual meeting
Subscribe for More Information
October 12, 2014
19:26 EDTSRPTPatient being evaluated at Boston hospital for possible Ebola, Boston Globe says
Health officials say that a man that recently traveled to Liberia is being assessed at Beth Israel Deaconess hospital in Boston for the Ebola virus, the Boston Globe says. Drug companies that are working on experimental Ebola treatments include Tekmira (TKMR), Sarepta (SRPT), BioCryst (BCRX), Chimerix (CMRX) and NewLink Genetics (NLNK). Reference Link
19:12 EDTSRPTCDC confirms Texas healthcare worker positive for Ebola
Subscribe for More Information
14:18 EDTSRPTNY's JFK Airport begins Ebola screenings, WSJ says
Subscribe for More Information
12:48 EDTSRPTTexas health-care worker tests positive for Ebola, WSJ says
Subscribe for More Information
1 | 2 | 3 | 4 | all recent news | >>

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use